Launch HN: RonanRX (YC S26) – Personalized Peptides and GLP-1s
Hacker News lloydarmbrust
YC-backed RonanRx wants to sell custom GLP-1 drugs end to end, from prescribing to delivery. It says owning the whole stack can make treatment cheaper and more personalized.
Based on reporting by Hacker News, lloydarmbrust — read the original for the full story.
Summary, retelling and take written by AI under human oversight; images are AI-generated illustrations. How we work · Report an error
RonanRx is pitching itself as a vertically integrated pharmaceutical company, and not just in the usual hand-wavy startup sense. The company says it is building software for prescribing, telehealth, compounding, manufacturing, and delivery, and is starting with GLP-1 drugs and peptides.
The founder story is unusual even by startup standards. Lloyd, one of the two founders, says he built one of the largest mask factories in the US during the pandemic, with the ability to produce a million masks a day. He says that operation leaned on machine learning, computer vision, and a vertically integrated setup, and eventually reached $50 million in revenue before masks stopped being a business people wanted.
RonanRx was born out of a very personal use case. After trying to lose weight with a six-month chicken-only diet and stalling out, Lloyd says his doctor suggested tirzepatide. He describes not just weight loss but a broader change: less “food noise,” less compulsive behavior, and improvements significant enough that his cardiologist began thinking his open-heart surgery, once expected in his 40s because of aortic stenosis, might be delayed until he is 70 or 80.
The company’s real target is the mess around customized medication. GLP-1s are sold in fixed doses, but RonanRx argues patients are not fixed at all. Its system is supposed to pull in medical records, current medications, labs, and wearable data, then follow a prescription through drug formulation, compounding, quality testing, dispensing, and distribution. The doctor stays in the loop the whole time, and the patient’s response becomes feedback for changing treatment.
RonanRx also says it can sell drugs more cheaply because it starts at the molecule and keeps control through the whole chain instead of paying middlemen at every step. The company says direct buyers usually pay 3x to 10x less. It is now asking for feedback from people who have built pharmacy, manufacturing, clinical, or EHR systems, which is a polite way of saying there are a lot of moving parts here and plenty of ways to break them.
My take — AI-written commentary, not fact-checked reporting
This is the kind of company that sounds obvious only after someone has suffered through the paperwork. Vertical integration in healthcare usually gets sold as destiny; here it at least has a real reason behind it: the current stack is a relay race of broken handoffs. The catch is that regulated systems are where software dreams go to meet reality, so the bar is not ambition, it’s boring execution.
Read more about this at: Hacker News
Related stories
Italian obesity digital clinic Holifya raises €2M to scale AI-supported GLP-1 care
Tech.eu · 2 weeks ago ·
37
Launch HN: Risklytics (YC S26) – Insurance brokerage for frontier tech companies
risklytics.ai · 3 weeks ago ·
11
A Unified OS for Drug Development: Our Investment in Cheiron
Menlo Ventures · 1 month ago ·
48